Protein Expression in Down Syndrome Brain - Lubec, G.; SpringerLink (Online service) (Vienna : Springer Vienna : Imprint: Springer, 2001)
Decreased alpha-endosulfine, an endogenous regulator of ATP-sensitive potassium channels, in brains from adult Down syndrome patients -- Developmental instability of the cerebellum and its relevance to Down syndrome -- Expression of the multidrug resistance P glycoprotein (Pgp) and multidrug resistance associated protein (MRP1) in Down syndrome brains -- Deterioration of the transcriptional, splicing and elongation machinery in brain of fetal Down Syndrome -- Fetal life in Down Syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure -- Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome -- Glial-neurotrophic mechanisms in Down syndrome -- Aberrant expression of dihy-dropyrimidinase related proteins-2, -3 and -4 in fetal Down Syndrome brain -- Decreased protein levels of complex I 30-kDa subunit in fetal Down Syndrome brains -- Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome -- Functional genomics of Down Syndrome: a multidisciplinary approach -- Unaltered expression of Fas (CD95/APO-1), Caspase-3, Bcl-2 and Annexins in brain of fetal Down syndrome: evidence against increased apoptosis -- Alteration of caspases and other apoptosis regulatory proteins in Down syndrome -- Expression of apoptosis related proteins: RAIDD, ZIP kinase, Bim/BOD, p21, Bax, Bcl-2 and NF-kB in brains of patients with Down syndrome -- Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down Syndrome and Alzheimer's disease -- Carbohydrate handling enzymes in fetal Down Syndrome brain -- Changes in nicotinic acetylcholine receptor subunits expression in brain of patients with Down syndrome and Alzheimer's disease -- Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down Syndrome -- Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome -- The brain in Down syndrome -- Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease -- Increased protein levels of heterogeneous nuclear ribonucleoprotein A2/B1 in fetal Down syndrome brains -- Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease -- Molecular neuropathology of transgenic mouse models of Down syndrome -- Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotoninergic innervation -- Expression profiles of proteins in fetal brain with Down syndrome -- Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down Syndrome: dysregulation of T-complex protein 1 -- ß-Amyliod precursor protein, ETS-2 and collagen alpha 1 (VI) chain precursor, encoded on chromosome 21, are not overexpressed in fetal Down syndrome: further evidence against gene dosage effect -- Reduction of nucleoside diphosphate kinase B, Rab GDP-dissociation inhibitor beta and histidine triad nucleotide-binding protein in fetal Down Syndrome brain -- Alteration of gene expression in Down's syndrome (DS) brains: its significance in neurodegeneration.
Keywords: Neurosciences; Molecular biology; Human genetics; Pediatrics; Pathology; Psychiatry; Neurosciences; Molecular Medicine; Human Genetics; Pediatrics; Pathology; Psychiatry